Cic edizioni internazionali
Functional Neurology

Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey

Original Article, 253 - 258
doi: 10.11138/FNeur/2013.28.4.253
Tag this article
Abstract
Enhanced HTML Full text PDF
The aim of this survey was to provide an overview of important issues relating to therapeutic strategies based on botulinum toxin type A injection for the treatment of patients with neurological disorders.
Two hundred and ten physicians from neurology and neurorehabilitation units in Italian hospitals answered a questionnaire exploring some clinical aspects of the use of botulinum toxin type A in patients with spasticity/dystonia. 66% of the physicians treated patients with dystonia, 80% treated adults with spasticity, and 35% treated children with cerebral palsy.
Palpation with no instrumental guidance was the injection technique most commonly used for treating patients with dystonia, spasticity and cerebral palsy; 57% of the physicians evaluated patients instrumentally before toxin injection, while 45% assessed postinjection improvements by instrumental means; 78% of the physicians prescribed (when appropriate) rehabilitation procedures after toxin injection. Our results seem to show that the routine use of botulinum toxin in clinics is far from standardized.

Vol. XXXII (No. 2) 2017 April/June

  1. The past and future of Functional Neurology
    D'Angelo E., Boller F., Wheeler-Kingshott C.G., Vanacore N., Sandrini G., Cisari C., Tamburin S., Baricich A.
    doi: 10.11138/FNeur/2017.32.2.061
  2. European core curriculum in neurorehabilitation
    Sandrini G., Binder H., Hömberg V., Saltuari L., Tarkka I., Smania N., Corradini C., Giustini A., Kätterer C., Picari L., Diserens K., Koenig E., Geurts A., Anghelescu A., Opara J., Tonin P., Kwakkel G., Golyk V., Onose G., Pérennou D., Picelli A.
    doi: 10.11138/FNeur/2017.32.2.063
  3. Object decision and multiple sclerosis: a preliminary study
    Caputi N., Matrella A., Totaro R., Raparelli C., Pontecorvo S., Di Giacomo D., Passafiume D.
    doi: 10.11138/FNeur/2017.32.2.069
  4. Cerebellar transcranial static magnetic field stimulation transiently reduces cerebellar brain inhibition
    Matsugi A., Okada Y.
    doi: 10.11138/FNeur/2017.32.2.077
  5. HLA-DRB1*15 association with multiple sclerosis is confirmed in a multigenerational Italian family
    Mosca L., Mantero V., Penco S., La Mantia L., De Benedetti S., MArazzi M.R., Spreafico C., Erminio C., Grassi L., Lando G., Zagaria M., Agostoni E., Protti A.
    doi: 10.11138/FNeur/2017.32.2.083
  6. The Italian real-life post-stroke spasticity survey: unmet needs in the management of spasticity with botulinum toxin type A
    Picelli A., Baricich A., Cisari C., Paolucci S., Smania N., Sandrini G.
    doi: 10.11138/FNeur/2017.32.2.089
  7. Sensitivity of multi-shell NODDI to multiple sclerosis white matter changes: a pilot study
    Schneider T., Brownlee W., Zhang H., Ciccarelli O., Miller D.H., Wheeler-Kingshott C.G.
    doi: 10.11138/FNeur/2017.32.2.097
  8. Ixcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection
    Fheodoroff K., Bhidayasiri R., Jacinto L.J., Chung T.M., Bhatia K., Landreau T., Colosimo C.
    doi: 10.11138/FNeur/2017.32.2.103
Last Viewed articles: la lista degli ultimi x visitati.
  1. Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey
    Smania N., Colosimo C., Bentivoglio A.R., Sandrini G., Picelli A.
    doi: 10.11138/FNeur/2013.28.4.253
credits